Dyandevi Mathure, Jyotsana R. Madan, Hemantkumar Arvind Ranpise, Rajendra Awasthi, Kamal Dua, Kishor Namdev Gujar
email@example.com , firstname.lastname@example.org
Dyandevi Mathure1*, Jyotsana R. Madan1, Hemantkumar Arvind Ranpise2, Rajendra Awasthi3, Kamal Dua4, Kishor Namdev Gujar2
1Department of Pharmaceutics, Smt. Kashibai Navale College of Pharmacy, Savitribai Phule Pune University, Pune, Maharashtra, India.
2Department of Pharmaceutics, Sinhgad College of Pharmacy, Savitribai Phule Pune University, Pune, Maharashtra, India.
3Amity Institute of Pharmacy, Amity University Uttar Pradesh, Noida 201303, Uttar Pradesh, India.
4Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, Ultimo New South Wales 2007, Australia.
Volume - 14,
Issue - 2,
Year - 2021
The aim of this work was to formulate buspirone hydrochloride (BH) NLCs for intranasal administration to improve BH bioavailability. The BH loaded NLCs were prepared by hot high-pressure homogenization technique using Precirol ATO 5, olive oil and tween 80 as solid lipid, liquid lipid and surfactant, respectively. Carbopol 934P and HPMC K4M were used to convert NLCs dispersion into NLCs based in-situ nasal gelling solution to improve its mucoadhesive property for intranasal administration. A factorial design approach was used to study the effect of independent variable (amount of Precirol ATO 5 and olive oil) on the dependent variables (particle size and percentage entrapment efficiency (%EE). The optimized formulation was characterized for particle size, zeta potential, %EE, and surface morphology. Fourier transform infrared (FTIR) spectroscopy was used to study the possible BH-lipid complex formation. Further, viscosity determination, stability studies, in- vitro drug release, ex-vivo skin permeation studies and ex-vivo nasal toxicity studies of BH loaded NLCs nasal gelling solution were carried out. The BH loaded NLCs (batch F8) showed particle size of 111.8nm, %EE of 78.34% and zeta potential of -44.3mV. Scanning electron microscopy (SEM) confirmed spherical shape of NLCs. In vitro drug release and ex vivo skin permeation studies of BH loaded NLCs and BH loaded NLCs in-situ nasal gelling solution showed 71.26% drug permeation.
Cite this article:
Dyandevi Mathure, Jyotsana R. Madan, Hemantkumar Arvind Ranpise, Rajendra Awasthi, Kamal Dua, Kishor Namdev Gujar. Formulation and Evaluation of Nano structured lipid carriers for intranasal delivery of Buspirone hydrochloride. Research J. Pharm. and Tech. 2021; 14(2):585-593. doi: 10.5958/0974-360X.2021.00105.0
Dyandevi Mathure, Jyotsana R. Madan, Hemantkumar Arvind Ranpise, Rajendra Awasthi, Kamal Dua, Kishor Namdev Gujar. Formulation and Evaluation of Nano structured lipid carriers for intranasal delivery of Buspirone hydrochloride. Research J. Pharm. and Tech. 2021; 14(2):585-593. doi: 10.5958/0974-360X.2021.00105.0 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-2-1
1. Li C, Wang J, Wang Y, Gao H, Wei G, Huang Y, Yu H, Gan Y, Wang Y, Mei L, Chen H. Recent progress in drug delivery. Acta Pharmaceutica Sinica B. 2019; 9(6): 1145-62.
2. Jain KK. An overview of drug delivery systems. In: Drug Delivery Systems. Humana, New York, NY. 2020; pp. 1-54.
3. Dey S, Mahanti B, Mazumder B, Malgope A, Dasgupta S. Nasal drug delivery: an approach of drug delivery through nasal route. Der Pharmacia Sinica. 2011; 2:94-106.
4. Kushwaha SKS, Keshari RK, Rai AK. Advances in nasal transmucosal drug delivery. Journal of Applied Pharmaceutical Science. 2011; 1:21-8.
5. Singh AK, Singh A, Madhv NS. Nasal cavity: A promising transmucosal platform for drug delivery and research approach from nasal to brain targeting. Journal Drug Delivery and Technology, 2012; 2(3): 22-23.
6. Mara Mainardes R, Cristina Cocenza Urban M, Oliveira Cinto P, Vinicius Chaud M, Cesar Evangelista R, Palmira Daflon Gremiao M. Liposomes and micro/nanoparticles as colloidal carriers for nasal drug delivery. Current Drug Delivery 2006; 3: 275-285.
7. Lim ST, Forbes B, Brown MB, Martin GP. Physiological factors affecting nasal drug delivery. Enhancement in drug delivery. New York. CRS Press. 2006; 356-370.
8. Singh AK, Mishra SK, Mishra G, Maurya A, Awasthi R, Yadav MK, Atri N, Pandey PK, Singh SK. Inorganic clay nanocomposite system for improved cholinesterase inhibition and brain pharmacokinetics of donepezil. Drug Development and Industrial Pharmacy. 2020; 46(1): 8-19.
9. Malekar NS, Gondkar S, Bhairav BA, Paralkar PS, Saudagar RB. Development of naratriptan hydrochloride in-situ nasal gel. Research Journal of Pharmacy and Technology. 2017; 10(4): 979-985.
10. Sanghavi S, Polara M, Patel D, Shah R, Patel J, Patel M. Nanoparticulate drug delivery to brain- A review. Research Journal of Pharmacy and Technology. 2012; 5(1): 8-13.
11. Eskandari S, Varshosaz J, Minaiyan M, Tabbakhian M. Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: In-vivo pharmacodynamics studies using rat electroshock model. International Journal of Nanomedicine. 2011; 6: 363-371.
12. Jaiswal A, Senthil V, Das TK. Design and development of valsartan loaded nanostrcutured lipid carrier for the treatment of diabetic wound healing. Research Journal of Pharmacy and Technology. 2019; 12 (6):26-38.
13. Bornare AS, Saudagar RB. Nanostrctured lipid carrier: A modern approach for transdermal drug delivery. Research Journal of Pharmacy and Technology. 2017; 10(8): 2784-2792.
14. Olbrich C, Gessner A, Kayser O, Müller RH. Lipid–drug conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. Journal of Drug Targeting. 2002; 10:387–96.
15. Talegaonkar S, Bhattacharyya A. Potential of lipid nanoparticles (SLNs and NLCs) in enhancing oral bioavailability of drugs with poor intestinal permeability. AAPS PharmSciTech. 2019; 20(3): 121.
16. Madan JR, Khobaragade S, Dua K, Awasthi R. Formulation, optimization, and in vitro evaluation of nanostructured lipid carriers for topical delivery of Apremilast. Dermatologic Therapy. 2020; e13370
17. Saudagar RB, Kulkarni MM. Review on in-situ nasal gel drug delivery system. Research Journal of Pharmacy and Technology. 2017;10(6):1870-6.
18. Loane C, Politis M. Buspirone: what is it all about? Brain Research. 2012; 1461:111-8.
19. Khan MS, Patil K, Yeole P, Gaikwad R. Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats. Journal of Pharmacy and Pharmacology. 2009; 61(5): 669-75.
20. Ravouru N, Kondreddy P, Korakanchi D. Formulation and evaluation of niosomal nasal drug delivery system of folic acid for brain targeting. Current Drug Discovery Technologies. 2013; 10(4):270-82.
21. Wavikar PR, Vavia PR. Rivastigmine-loaded in situ gelling nanostructured lipid carriers for nose to brain delivery. Journal of Liposomes Research. 2015; 2(25): 141-149.
22. Gaba B, Fazil M, Khan S, Ali A, Baboota S, Ali J. Nanostructured lipid carrier for topical delivery of terbinafine hydrochloride. Bulletin of Faculty of Pharmacy, Cairo University. 2015; 53: 147-159.
23. Ranpise HA, Gujar KN, Mathure D, Satpute PP, Awasthi R, Dua K, Madan JR. Skin targeting of oxiconazole nitrate loaded nanostructured lipid-carrier gel for fungal infections. Pharmaceutical Nanotechnology. 2018; 6(3): 192-200.
24. Joshi M, Patravale V. Nanostructured lipid carrier (NLC) based gel of celecoxib. International Journal of Pharmaceutics. 2008; 346(15):124-32.
25. Schäfer-Korting M, Mehnert W, Korting HC. Lipid nanoparticles for improved topical application of drugs for skin diseases. Advanced Drug Delivery Reviews. 2007; 59: 427-43.
26. Madan J, Pawar A, Patil RB, Awasthi R, Dua K. Preparation, characterization and in-vitro evaluation of tablets containing microwave assisted solid dispersions of apremilast. Polymers in Medicine. 2019; 48(1):17–24.
27. Kaur K, Nautiyal U, Singh D. Nanostructured lipid carrier for bioavailability enhancement. International Journal of Advanced Science and Technology. 2015; 2(1): 1–9.
28. Madan JR, Ghuge NP, Dua K. Formulation and evaluation of proniosomes containing lornoxicam. Drug Delivery and Translational Research. 2016; 6(5):511–8.
29. Gupta H, Sharma A. Ion activated bioadhesive in-situ gel of clindamycin for vaginal application. International Journal of Drug Delivery. 2009; 1:32-40.
30. Seju U, Kumar A, Sawant KK. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose to brain delivery: in vitro and in-vivo studies. Acta Biomaterialia. 2011; 7:4169-4176.
31. Sood S, Jain K, Gowthamarajan K. Optimization of curcumin nanoemulsion for intranasal delivery using design of experiment and its toxicity assessment. Colloids and Surfaces B: Biointerfaces. 2014; 111(3):30-37.
32. Mc Clements DJ. Food emulsions: principles, practices, and techniques. 3rd edition. CRC Press, Florida, United States. 2015; 3:690.
33. Harde H, Agrawal AK, Katariya M, Kale D, Jain S. Development of a topical adapalene-solid lipid nanoparticle loaded gel with enhanced efficacy and improved skin tolerability. RSC Advances. 2015; 5(55):4317–29.
34. Mandlik SK, Nandare DS, Joshi MM, Chudiwal PD, Jain KS. Statistical optimization of orodispersible tablets containing telmisartan using factorial design and response surface methodology. Research Journal of Pharmacy and Technology. 2009; 2(3):548-51.
35. Abdelbar GA, Aburahma MH. Oro-dental mucoadhesive proniosomal gel formulation loaded with lornoxicam for management of dental pain. Liposome Research. 2015; 25(2): 107-21.
36. Jain SP, Shah SP, Rajadhyaksha NS, Singh PS PP, Amin PD. In-situ ophthalmic gel of ciprofloxacin hydrochloride for once a day sustained delivery. Drug Development and Industrial Pharmacy. 2008; 34(4): 445-52.